Anixa Biosciences, Inc.

Research, Patent monetization, Patent assertion, Research, Biotechnology: pharmaceutical preparations
Founded in 1982
San Jose, California
http://www.anixa.com
None

About Anixa Biosciences, Inc.

Anixa Biosciences (NASDAQ:ANIX) is a clinical stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer--specifically triple negative breast cancer (TNBC), the most lethal form of the disease--as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the company to continually examine emerging technologies in complementary fields for further development and commercialization.

Company Metrics

  • Employees: 11-50
  • Monthly Visits: None
  • Tech Stack: None active products

Financial Information

  • Estimated Revenue: Less than $1M
  • Total Funding: 7.8M None
  • Last Funding: 3.5M None (None)
  • Funding Status: None

Technology Stack

Anixa Biosciences, Inc. actively uses None products in their tech stack.

Market Presence

Industries: Research, Patent monetization, Patent assertion, Research, Biotechnology: pharmaceutical preparations

Headquarters: San Jose, California